Evidence map›Paper›PMID 33634589›Full record

Trial reportPediatric obesity2021

Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.

Megan O Bensignor, Eric M Bomberg, Carolyn T Bramante, T V S Divyalasya, Paula M Hale, Chethana K Ramesh, Kyle D Rudser, Aaron S Kelly

Registry-linked trialOpen access · hybridFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric obesity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01541215. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01541215 phase3completed

Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes

Ran2012Enrolled135Registered outcomes80Posted comparisons4ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Metformin, Placebo
PMID 31034184other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Megan O BensignorDepartment of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.ORCID 0000-0002-9341-1858
Eric M BombergDepartment of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Carolyn T BramanteCenter for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
T V S DivyalasyaNovo Nordisk, Bangalore, India.
Paula M HaleNovo Nordisk Inc., Plainsboro, New Jersey, USA.
Chethana K RameshNovo Nordisk, Bangalore, India.
Kyle D RudserCenter for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Aaron S KellyDepartment of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
University of Minnesota Medical Center · USNovo Nordisk (India) · INNovo Nordisk (United States) · USUniversity of Minnesota · US

Funding

Anti-obesity pharmacotherapy to decrease BMI and improve insulin sensitivity in adolescents with obesity and type 2 diabetesK23DK129721 · UNIVERSITY OF MINNESOTA · 2025 to 2025
$201k
NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR002494NIDDK NIH HHS K23 DK124654NIDDK NIH HHS K23 DK125668NIDDK NIH HHS K23 DK129721
6 · The paper itself

Abstract

backgroundWeight loss in children and adolescents with type 2 diabetes (T2D) is associated with improved glycaemic control.

objectivesTo assess the effects of liraglutide vs placebo on body mass index (BMI) and weight parameters in children and adolescents with T2D using data from the ellipse trial (NCT01541215).

methodsThe ellipse trial randomized participants (10-<17 years old, BMI >85th percentile, T2D, glycated haemoglobin [HbA

resultsIn total, 134 participants were included. There were statistically significant differences between groups in certain parameters, including absolute BMI (estimated treatment difference [ETD] -0.89 kg/m

conclusionsCompared with placebo, liraglutide was associated with statistically significant reductions in BMI/weight parameters at week 52, but not week 26, in children and adolescents with T2D.

Indexed as

Body Mass IndexDiabetes Mellitus, Type 2LiraglutideWeight LossAdolescentChildGlycated HemoglobinHumansTreatment OutcomeGlycated HemoglobinLiraglutideanti-obesity agentsbody mass indexliraglutidepaediatric obesityweight

Identifiers

PMID33634589
PMCPMC8277686
OpenAlexW3133181364

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.